Is it appropriate to prescribe dextroamphetamine 10 mg taken twice daily for an adult (or adolescent ≥13 years) with attention‑deficit/hyperactivity disorder or narcolepsy who has no contraindications?

Dextroamphetamine 10mg Twice Daily for ADHD or Narcolepsy

Yes, dextroamphetamine 10 mg twice daily is an appropriate and evidence-based prescription for adults and adolescents ≥13 years with ADHD or narcolepsy who have no contraindications.

Dosing Appropriateness

This regimen falls well within established guidelines for both conditions:

For ADHD

• The dose of 10 mg twice daily (20 mg total daily) is within the recommended therapeutic range 1. Guidelines specify starting dextroamphetamine at 2.5-5 mg and titrating in 2.5-5 mg increments weekly 1.
• Maximum total daily doses reach 40 mg for amphetamines in children/adolescents, with adults sometimes requiring up to 40 mg total daily or 0.9 mg/kg 1.
• The twice-daily dosing schedule aligns with guideline recommendations to dose after breakfast and lunch, avoiding late-day administration to minimize insomnia 1.

For Narcolepsy

• The FDA-approved dosing for narcolepsy explicitly includes this regimen 2. For patients ≥12 years, the label states: "start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained."
• The usual dose range is 5-60 mg daily in divided doses 2.
• First dose should be given on awakening, with additional doses at 4-6 hour intervals 2.

Evidence Quality and Efficacy

Amphetamines demonstrate superior efficacy compared to other ADHD medications 3. A comprehensive 2018 network meta-analysis of 133 trials found:

• Amphetamines showed the largest effect size for ADHD core symptoms in both children/adolescents (SMD -1.02) and adults (SMD -0.79) 3
• Amphetamines were superior to methylphenidate, atomoxetine, and modafinil in head-to-head comparisons 3
• Approximately 70% of patients respond to either dextroamphetamine or methylphenidate alone, with nearly 90% responding if both are tried 1

For narcolepsy, dextroamphetamine has demonstrated clinically significant improvements in excessive daytime sleepiness, though the overall quality of evidence is very low 4.

Critical Safety Monitoring Requirements

Before prescribing, you must assess for absolute contraindications 1:

Absolute contraindications:

• Concomitant MAO inhibitor use (risk of hypertensive crisis and cerebrovascular accident)
• Active psychosis or schizophrenia (stimulants are psychotomimetic)
• Glaucoma (may increase intraocular pressure)

Relative contraindications requiring careful assessment:

• Cardiac disease: Obtain baseline blood pressure, pulse, and cardiac history including family history of sudden death or ventricular arrhythmia 1, 2
• History of stimulant abuse (not absolute; requires closer monitoring) 1

Required baseline assessments 1:

• Blood pressure and pulse
• Height and weight
• Physical examination
• Cardiac history and family history of sudden death

Ongoing monitoring schedule 1:

• Weekly contact during initial titration (2-4 weeks)
• Monthly visits until symptoms stabilized
• Quarterly blood pressure and pulse checks for adults
• Annual vital signs for children/adolescents
• Weight monitoring at each visit (appetite suppression is common)

Common Pitfalls and Management

Side effects to systematically assess 1, 5:

• Decreased appetite and weight loss (most common)
• Insomnia (dose early in day; avoid late afternoon/evening doses)
• Increased blood pressure and pulse
• Headaches
• Irritability or agitation

Tolerability concerns 3:

• Amphetamines showed inferior tolerability compared to placebo in both children/adolescents (OR 2.30) and adults (OR 3.26)
• However, most side effects are dose-dependent and reversible with dose reduction or discontinuation 6

Special Population Considerations

Adolescents: Screen for substance abuse before initiating treatment 7. Monitor for diversion risk, as dextroamphetamine is a Schedule II controlled substance with abuse potential 4, 2.

Pregnancy: Based on animal data, dextroamphetamine may cause fetal harm; human data are insufficient 4, 2.

Comorbidities that are NOT contraindications (contrary to older package insert warnings) 1:

• Motor tics/Tourette's syndrome (controlled studies show methylphenidate doesn't worsen tics; amphetamines may be slightly more problematic)
• Anxiety disorders (patients with comorbid anxiety improve on stimulants)
• Stabilized seizure disorders (can use stimulants once anticonvulsants have stabilized seizures)

Clinical Algorithm

1. Confirm diagnosis of ADHD (meeting DSM criteria with functional impairment in ≥2 settings) or narcolepsy
2. Screen for contraindications (MAO inhibitors, active psychosis, glaucoma, uncontrolled cardiac disease)
3. Obtain baseline measurements (BP, pulse, height, weight, cardiac history)
4. For ADHD: Consider methylphenidate as first-line in children/adolescents 5, 3; amphetamines are preferred in adults 3
5. Prescribe dextroamphetamine 10 mg twice daily (after breakfast and lunch)
6. Monitor weekly during titration via phone or visit with symptom rating scales
7. Adjust dose in 5-10 mg increments weekly if needed, up to maximum 40 mg total daily 1
8. Maintain quarterly monitoring of vital signs and side effects once stabilized

This prescription represents evidence-based, guideline-concordant care when appropriately monitored 1, 5, 1, 2, 3.